KR20170111095A - Composition for preventing and treating ischemic retinopathy comprising transferrin - Google Patents

Abstract

The present invention relates to a composition for the prevention and treatment of ischemic retinopathy comprising transferrin as an active ingredient, and the composition for preventing and treating ischemic retinopathy according to the present invention is a composition for preventing and treating ischemic retinopathy by preventing retinal ganglion cell apoptosis, And is useful for prevention and treatment of ischemic retinopathy.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing and treating ischemic retinopathy,

The present invention relates to a composition for preventing and treating ischemic retinopathy comprising transferrin.

Ischemic retinopathy is a symptom of a disease that causes damage to the retina, optic nerve, and optic nerve cell due to insufficient supply of blood to the retina due to various causes and ultimately to impaired visual function. Ischemic retinopathy is a condition characterized by ischemic optic neuropathy-induced diseases and conditions (vascular inflammatory diseases such as giant cell arteritis, nodular polyarteritis, Chur-Strauss syndrome, multiple vasculitis granulomatosis, rheumatoid arthritis, hypercholesterolemia, , Diabetic retinopathy, occlusion of retinal vessels, and ophthalmic artery occlusion, which are associated with elevated intraocular pressure (IOP) (Glaucoma) is one of the representative diseases.

Glaucoma is a disease caused by the combination of various genetic factors and environmental factors. It is a terrible disease that eventually leads to blindness if not treated. Among primary glaucoma, primary open-angle glaucoma (POAG) is the most common and is classified into normal tension glaucoma (NTG) and high tension glaucoma (HTG). Unlike other retinal diseases, primary open angle glaucoma is a chronic, degenerative retinal disease characterized by enlargement of the optic nerve cup by apoptosis of retinal ganglion cells (RGC) (Sewon Kim, et al., Molecular Vision, Vol. 21, pp. 548-554, 2015).

The causes of glaucoma are known to be caused by abnormal intraocular pressure (IOP) increase, but it is not possible to diagnose glaucoma only by high intraocular pressure. In addition, , Family history, etc.

Currently, treatments for glaucoma include laser trabeculoplasty, laser iridotomy, peripheral iridectomy, trabeculectomy, aqueous shunt operation, and gointotomy ), But the surgical treatment is not applicable to all patients, and there is a great restriction as well as a low success rate and a high cost of social and economic burden .

Currently, only medicines that have a role of lowering the intraocular pressure have been developed, and the medicines have been developed only for the treatment of burning sensation, itching, eye rash, pulse change, asthma deterioration, mouth dryness, visual field disturbance, eyebrow length change, It is necessary to develop a new glaucoma prevention and treatment agent.

Iron, on the other hand, is an essential element of life on earth, but unstable iron alone in the cell promotes the production of free radicals, so it must be managed very carefully. In the case of humans, iron binds to the transferrin protein. Approximately 70% of transferrin is present in the form of apotransferrin, which is not bound to iron, so that excess iron is not bound to proteins in the blood, Thereby preventing it from existing.

Transferrin is an 80 kDa glycoprotein that is known to carry iron ions. Recently, apotransferrin has been known to protect cells in various tissues and cells. For example, in the intracerebral hemorrhage model, iron-bound transferrin has been shown to have no such effect, whereas apotransferrin prevents the damage of primary cortical neurons by iron-dependent neurotoxicity of hemoglobin (Jing Chen-Roetling, et al., Neuropharmacology, Vol 60, pp. 423-431, 2011). Apotransferrin has also been shown to have therapeutic effects in neurodegenerative diseases.

US Patent Application No. US 2013-9159394 claims the use of transferrin in relation to ophthalmic diseases, but the type of disease is different from glaucoma, and the animal model used in the experiment induces the photoreceptor cell death of the retina. Different from the invention, there is a difference in indications to be treated.

Accordingly, the present inventors have made intensive efforts to solve the above-mentioned problems and to develop a composition capable of effectively preventing and treating ischemic retinopathy. As a result, in the case of a composition containing transferrin as an active ingredient, It is possible to prevent and cure ischemic retinopathy. Thus, the present invention has been completed.

It is an object of the present invention to provide a composition for preventing and treating ischemic retinopathy which contains transferrin.

In order to achieve the above object, the present invention provides a composition for preventing and treating ischemic retinopathy comprising transferrin as an active ingredient.

 The composition for preventing and treating ischemic retinopathy according to the present invention is excellent in preventing and treating ischemic retinopathy by preventing apoptosis of retinal ganglion cells, and is useful for prevention and treatment of ischemic retinopathy.

FIG. 1 (A) shows a retina region set to count the number of retinal ganglion cells around an optic disc, FIG. 1 (B) shows a retina region cut in a superior to inferior direction cup) was tunnelled (TUNEL staining) and then counted to count the number of stained retinal ganglion cells.
FIG. 2 shows the result of measuring retinal ischemia reperfusion model in terms of time, after inducing an ocular hypertensive phenomenon, and then expressing the level of transferrin in the retina ischemia reperfusion model.
FIG. 3 shows the results of measuring the concentration of total iron and ferrous iron ( ^bivalent iron, Fe ²⁺ ) ions over time after inducing an ocular hypertensive phenomenon in a retinal ischemia-reperfusion model.
FIG. 4 shows the results of measuring the effect of transferrin on body weight and intraocular pressure of an animal model after inducing an ocular hypertensive phenomenon in retinal ischemia-reperfusion model and treating transferrin.
FIG. 5 shows the result of hypertensive phenomenon induced by retinal ischemia-reperfusion model, transferrin treatment, and the state of retinal ganglion cells compared with the control group by tunneling.
FIG. 6 shows the results of measuring the number of retinal ganglion cells surviving over time after inducing an ocular hypertensive phenomenon in a retinal ischemia-reperfusion model.
Figure 7 shows the results of comparing the number of retinal ganglion cells surviving over time after inducing hypertension in retinal ischemia reperfusion model and treating transferrin with the control group.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.

In the present invention, the effect of transferrin to prevent and treat ischemic retinopathy was examined.

In the present invention, retinal ischemia is induced in an animal model of glaucoma, and apoptosis is treated to suppress the apoptosis of retinal ganglion cells, which is a typical symptom of glaucoma without changes in intraocular pressure.

That is, in one embodiment of the present invention, retina ischemic reperfusion animal model designed to cause apoptosis of retinal ganglion cell, which is a typical symptom of glaucoma, causes retinal ischemia, And injected into the abdominal cavity of the model. Thereafter, the retina was incised to observe the degree of death of the retinal ganglion cells in the area shown in Fig. 1, and it was confirmed that the apoptosis of the retinal ganglion cells was remarkably inhibited when treated with apotransferrin 5 to Fig. 7).

Accordingly, the present invention relates to a composition for preventing and treating ischemic retinopathy comprising transferrin as an active ingredient.

In the present invention, the transferrin may be any transferrin protein that can bind iron, but may be aprotransferrin. Most preferably, the amino acid sequence of SEQ ID NO: Is displayed.

The transferrin of the present invention has a homology of 75%, preferably 85%, preferably 90%, more preferably 95% or more, to the amino acid sequence of SEQ ID NO: 1 and is capable of preventing the cell death of retinal ganglion cells But the present invention is not limited thereto and it is obvious in the art that the glycation form of the transferrin of the present invention also falls within the scope of the present invention.

In the present invention, the ischemic retinopathy is applicable to any disease related to optic nerve damage caused by the death of the retinal ganglion cells without limitation, but it is preferable that the disease causing ischemic optic neuropathy (vascular inflammatory disease such as giant cell arteritis, Hypertension, hypertension, hypertension, sleep apnea, cardiac and spinal surgery, radiation therapy), diabetic retinopathy, retinal vascular occlusion, ophthalmic artery occlusion And glaucoma, and is most preferably selected from the group consisting of glaucoma.

In the present invention, the glaucoma may be an open-angle glaucoma, but the present invention is not limited thereto.

It is known that transferrin treatment is known to have an effect on ophthalmic diseases (US 2013-9159394), but in the above-mentioned prior art, a mouse model that induces the photoreceptor cell death induction in the retina is used To examine the effect of preventing the photoreceptor cell death, the experiment on the retinal ganglion cell related to the ischemic retinopathy claimed in the present invention was not performed, and the effect on the ophthalmic disease was different from that of the ischemic retinopathy Respectively.

In contrast, the present invention demonstrates the effect of preventing and treating ischemic retinopathy of transferrin using an animal model that induces increased intraocular pressure and cell death of retinal ganglion cells, which is one of the typical symptoms that occur when glaucoma occurs.

In the present invention, the transferrin can be used without restriction on the principle, mechanism, mechanisms and mechanism of action of a composition for use in the prevention and treatment of ischemic retinopathy. Preferably, the transferrin is used to prevent ischemic retinopathy Prevention and treatment of the disease.

The term "treatment" as used herein refers to the treatment of ischemic retinopathy which reverses the symptoms of the disease, as well as inhibiting or alleviating one or more symptoms caused by retinopathy or any resulting from the administration of the composition, . The term "prophylactic" in the present invention means any action that inhibits ischemic retinopathy or delays the onset of ischemic retinopathy upon administration of the composition.

The composition of the present invention may contain, in addition to the transferrin of the present invention, physiologically compatible excipients and / or additives that can be routinely selected and used in the art. The composition according to the present invention may further include such excipients and / or additives as an isotonic agent, a buffer, a surfactant, a stabilizing polymer, a preservative, a viscosity increasing agent, an antioxidant and the like, It will be apparent to those skilled in the art that other ingredients may be further included.

The isotonicity agent is used to adjust the tonicity of the composition, preferably the isotonicity of natural tears used in ophthalmic compositions, such as, for example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sugars Can be adjusted to similar physiological appearances by adding to the composition a polyol (e.g., glucose, glucose, fructose, glucose, sucrose, glucose, fructose, galactose) . The amount of such isotonizing agent can be appropriately selected depending on the specific reagent to be added.

The buffer may be at least one selected from those conventionally used in the art, for example, sodium phosphate, sodium acetate, sodium citrate, sodium borate, boric acid and the like, Can be used. The concentration varies depending on the reagent used, but is preferably selected to maintain a pH of 5 to 8, more preferably 5 to 7.

These surfactants are used to dissolve the active ingredient and stabilize colloidal dispersions such as micellar solutions, microemulsions, emulsions and suspensions, such as polysorbate, poloxamer, polyoxyl 40 stearate, Free, tyloxapol, triton (e.g., Triton X114) and / or sorbitan monolaurate may be used.

The stabilizing polymer may be a polyelectrolyte selected from a crosslinked polyacrylate system such as carbomer and Pemulen TM, specifically 0.1 to 0.5% (w / w) of Carbomer 974P (polyacrylic acid) .

The preservative is used to prevent microbial contamination during use. Examples of the preservative include benzalkonium chloride, chlorobutanol, benzododecylium bromide, methylparaben, propylparaben, phenylethyl alcohol, edentate disodium, sorbic acid, poly Quaternium-1 or other agents known in the art may be used.

The viscosity enhancer is used to increase the viscosity of the carrier. Examples thereof include polysaccharides (e.g., hyaluronic acid) and its salts, chondroitin sulfate and its salts, dextran, various polymers of cellulose type, vinyl polymers, and acrylic acid polymers But are not limited to these.

Antioxidants may be added to the compositions of the present invention to prevent the active ingredient from being oxidized during storage. Examples of such antioxidants include, but are not limited to, vitamin E and its analogs, ascorbic acid and derivatives, and butylated hydroxyanisole (BHA).

The composition for preventing and treating ischemic retinopathy comprising the transferrin of the present invention may further comprise a pharmaceutically acceptable carrier and may be formulated together with the carrier.

As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not irritate the organism and does not interfere with the biological activity and properties of the administered compound. Examples of the pharmaceutical carrier which is acceptable for the composition to be formulated into a liquid solution include sterilized and sterile water suitable for the living body such as saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare formulations for injection, such as aqueous solutions, suspensions, emulsions, etc., or tablets.

The composition for preventing and treating ischemic retinopathy comprising the transferrin of the present invention and a pharmaceutically acceptable carrier can be applied to any formulation containing it as an active ingredient and can be manufactured into oral or parenteral formulations. The pharmaceutical formulations of the present invention may be formulated for oral, rectal, nasal, topical (including ball and sublingual), subcutaneous, vaginal or parenteral, intramuscular subcutaneous and intravenous Or the like) or a form suitable for administration by insufflation.

Examples of the formulations for parenteral administration containing the composition of the present invention as an active ingredient include injection forms such as subcutaneous injection, intravenous injection or intramuscular injection, suppository injection method, or aerosol agent for inhalation through a respirator . ≪ / RTI > For formulation into injectable formulations, the compositions of the present invention may be formulated as solutions or suspensions in water with stabilizers or buffers in water, and formulated for unitary administration of ampoules or vials. For injection into suppositories, it may be formulated into rectal compositions such as suppositories or enema preparations, including conventional suppository bases such as cocoa butter or other glycerides. When formulated for spraying, such as an aerosol formulation, a propellant or the like may be formulated with the additive such that the water-dispersed concentrate or wet powder is dispersed.

In another aspect, the present invention relates to a method for preventing or treating ischemic retinopathy comprising administering a composition for the prevention and treatment of ischemic retinopathy comprising said transferrin.

As used herein, the term "administering" means introducing the pharmaceutical composition of the present invention to a patient in any suitable manner. The route of administration of the composition of the present invention can be administered through various routes of oral or parenteral administration as long as it can reach the target tissues. Specifically, it can be administered orally, rectally, topically, intravenously, intraperitoneally, intramuscularly, Transdermal, intranasal, inhalation, intra-ocular or intradermal routes.

The method of treatment of the present invention includes administering a pharmaceutical effective amount of the composition for the prevention and treatment of ischemic retinopathy of the present invention. It is obvious in the art that the appropriate total daily dose may be determined by the treatment within the scope of sound medical judgment. The specific therapeutically effective amount for a particular patient will depend upon a variety of factors, including the type and extent of the response to be achieved, the specific composition, including whether or not other agents are used, the age, weight, general health status, sex and diet, The route of administration and the fraction of the composition, the duration of the treatment, the drugs used or co-used with the specific composition, and the like, well known in the medical arts. Therefore, the effective amount of the composition for the prevention or treatment of ischemic retinopathy suitable for the purpose of the present invention is preferably determined in consideration of the above-mentioned matters.

In addition, the therapeutic method of the present invention can be applied to any animal in which the optic nerve is damaged due to the death of the retinal ganglion cell and diseases that can lead to blindness can occur, and the animal is not only humans and primates but also cows, pigs, , Livestock such as dogs and cats.

[Example]

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are for illustrating the present invention only, and the scope of the present invention is not limited by these examples.

<Method> The method used in this experiment is as follows.

Male Sprague-Dawley (SD) rat adults (7-8 weeks old, 250-300 g) were raised in a 12-hour day-night cycle with a standard diet containing labitum.

&Lt; Induction of transient ischemia-reperfusion with high intraocular pressure > A mixture of 15 mg / kg of xylazine hydrochloride and 50 mg / kg of tiletamine plus zolazepam was intraperitoneally administered to rats , The hypothermia reduces the retinal damage due to ischemia reperfusion, so the experiment was carried out on a heating pad to maintain the body temperature of 36-37 ° C. The pupil was treated with 1% tropicamide to dilate the pupil. A 30-gauge infusion needle connected with a pressure device to the left eye was carefully placed so as not to injure the iris, the lens, and the corneal endothelium After insertion, intraocular pressure was maintained at 180 mmHg for 1 hour. Retinal ischemia was confirmed as a whitening phenomenon of the iris by inserting a reperfusion needle without increasing intraocular pressure in the right eye. Rats in which body temperature was lowered to 35 ° C or less were excluded, and only rats with an intraocular pressure of 175-180 mmHg were used for analysis.

<Apotransferrin treatment> Lyophilized human plasma apotransferrin was dissolved in phosphate-buffered saline (PBS) at a concentration of 25 μg / μl, and mice treated with PBS alone were used as a control. 400 μl of PBS or apotransferrin solution was intraperitoneally injected two days before, one day before, immediately before, immediately after, and the next day of ischemia reperfusion. Changes in ischemic IOP were measured using an Icare TONOLAB tonometer, and weights of the mice were periodically measured for 8 days to observe whether there was any change

<Tissue Sample Preparation for Immunohistochemical Staining Analysis> When each eye was extracted from an experimental rat, a specific mark was placed at 12 o'clock position to distinguish the upper, lower, left and right eyes of the eye. After removing the anterior segment and the glass of the eyeball, the posterior eye cup was fixed overnight at 4 ° C in a solution of 4% paraformaldehyde (PFA) in PBS. Fixed patches were washed several times with PBS, then immersed in PBS solution containing 30% sucrose, incubated at 4 ° C for 6 hours to perform low temperature cryoprotection, and mixed with optimal cutting temperature compound (OCT) Freezing in nitrogen. The specimens were frozen at a temperature of minus 12 ◦ C at 20 ◦ C in a superior to inferior orientation, including the optic nerve, on a Superfrost plus microscope slide. Immunohistochemical staining and tunneling &Lt; / RTI &gt;

A wholemount immunohistochemical analysis was performed by cutting the array into four circles having four quadrants so that the retina was placed flat on the slide (FIG. 1A). The retina was carefully removed from the bottom in the upper direction and then immersed in PBS mixed with 0.5% Triton-X100 at -80 ° C. for 15 minutes and then immersed in PBS mixed with 2% Triton-X100 at 4 ° C. overnight And permeabilization was performed. After washing with PBS, the cells were incubated overnight at 4 ° C with a primary goat anti-Brn3a antibody (SC-37984, 100-fold dilution), 2% donkey serum and 2% Triton X-100, washed with PBS, goat Alexa594 (A11058, 500-fold dilution) secondary antibody and 2% donkey serum, and washed with PBS. To stain the nuclei, the retina was treated with DAPI (4'6-Diamidine-2'-phenylindole), placed on a coated slide using VECTARSHIELD Mounting Media, covered with cover slides and confocal microscopy (Ism780, Zeiss) Respectively.

<Measurement of Living Retinal Ganglion Cell Count> A scan image enlarged by 20 times was obtained to measure the number of retinal ganglion cells (RGC) labeled with Brn3a. The central region, mid-peripheral region, and peripheral region of the 1, 2, and 3 mm distance from the optic nerve head were set in the whole retinal image, and the ZEN program (microscope and imaging software , ZEISS) was used to extract 425 μm × 425 μm 3D images of each quadrant for one central portion, two middle portions and four peripheral portions (FIG. 1A). In the extracted images, Brn3a-labeled retinal ganglion cells were measured using the Imaris program filtering option (spot diameter threshold: 7.5 μm or more).

Western blotting analysis Rats were euthanized, and the cornea, lens, and vitreous were removed and the retina was quickly cut and stored at 80 ° C. A retina sample was added to a solution containing a protease inhibitor in a radioimmunoprecipitation assay buffer and pulverized. After 10 minutes of tissue culture, the supernatant was collected by centrifugation at 15,000 rpm for 10 minutes at 4 ° C, and the total protein concentration was measured in the retinal extract. SDS was added and boiled at 100 ° C for 10 minutes. Then, 50 μg of the whole protein was transferred to SDS-polyacrylamide gel, electrophoresed and transferred to PVDF (polyvinylidenedifluoride) membrane. The membrane was blocked with TBST buffer (mixture of Tris-buffered saline and Tween 20) containing 5% non-fat dry milk for 1 hour and polyclonal anti-transferrin antibody (NBPI-97472, 1000 fold dilution), rat monoclonal anti-ceruloplasmin antibody (sc-135866, 1000-fold dilution) and chlorpolyol anti-actin antibody (sc-1616, 1000-fold dilution) , Incubated at 4 ° C overnight, washed several times with TBST buffer, and reacted with a secondary antibody (10,000-fold dilution) of rabbit, mouse and goat IgG conjugated with horseradish peroxidase (HRP).

<TUNEL staining> Retinal ischemia was induced and after 6 hours, a 12 μm thick retinal frozen cut sample was prepared, washed with PBS, and incubated with terminal deoxynucleotidyl transferase (TMR) and TMR red Lt; RTI ID = 0.0 &gt; 37 C &lt; / RTI &gt; for 1 hour. After several washes with PBS again, the frozen cut samples were loaded using VETARSHIELD mounting media with DAPI.

The entire retinal image was acquired with a 20x magnification of the Confocal microscope (ZEISS). Each region of the lobe was divided into 1 mm, 2 mm, and 3 mm regions from the optic nerve and designated as center, middle, and periphery. The number of tunnel-gated retinal ganglion cells in the area of 425 μm was measured (FIG. 1B).

<Measurement of Iron Concentration> In order to measure the concentration of total iron and ferrous iron, the retina was separated, pulverized with a 10-fold volume of iron assay buffer, and centrifuged at 16000 rpm for 10 minutes. The solution was recovered. Standard samples (0, 2, 4, 6, 8, 10 nmol Fe ^{2 +} / well) and retinal samples were placed in 96-well plates and 5 μl of iron reducer and iron assay buffer And incubated for 30 minutes at 37 ° C. No iron reducer was added to the wells to measure the primary iron concentration. Then, 100 μl of iron probe was injected into each well and cultured in a dark room at 25 ° C for 1 hour. The iron concentration was then measured by absorbance at 600 nm.

[Example 1: Analysis of expression patterns of transferrin and ceruloplasmin by glaucoma]

Retinal ganglion cells were induced by ischemia reperfusion in retinal ganglion cell apoptosis model. Retina samples at 12 and 24 hours after induction of ischemia reperfusion were prepared as a control group to detect expression patterns of transferrin and ceruloplasmin . As a result, it was confirmed that the degree of expression of transferrin and ceruloplasmin was increased after induction of ischemia reperfusion after 12 hours and 24 hours (FIG. 2)

[Example 2: Analysis of total iron concentration change in ischemic retina]

It is already known that the concentration of iron alone increases in retinal ischemia without binding to proteins, but its source is not yet known. In order to determine whether it was from the outside of the eyeball or from the iron-binding protein inside the eyeball, the total iron concentration and the ferrous iron concentration of the crushed retinal tissue were measured before the ischemia, 12 hours, 24 hours And over 48 hours. As a result, it was confirmed that in the retinal ischemia reperfusion, the total iron concentration and ferrous iron concentration in the retina were not significantly changed before and after retinal ischemia (FIG. 3). Thus, it can be seen that iron is not introduced into the retina from the outside of the retina by ischemia reperfusion.

[Example 3: Analysis of body weight and intraocular pressure after apotransferrin treatment]

Human apotransferrin protein was intraperitoneally injected two days before, one day before, immediately after, and after 5 days of ischemia reperfusion, and intraocular pressure was measured before and 6 days after retinal ischemia and periodic body weight was measured. As a result, it was confirmed that no side effects such as increased intraocular pressure did not occur even after treatment with apotransferrin, and no change in body weight (FIG. 4).

[Example 4: Confirmation of apoptosis-preventing effect of retinal ganglion cell by apotransferrin]

To confirm whether apoptosis caused by retinal ischemia was prevented by apotransferrin, retina samples after 6 hours of induction of retinal ischemia were prepared as a control group and confirmed by tunneling. As a result, it was confirmed that the number of tunnel-positive retinal ganglion cells in which apoptosis and apoptosis of the nuclei were observed compared to the control group (Fig. 5).

[Example 5: Analysis of survival rate of retinal ganglion cells by apotransferrin]

To investigate the long-term effects of apotransferrin on the survival of retinal ganglion cells in retinal ischemia-reperfused animal models, retina ischemia was induced, and retinal ischemia was induced at 3 days, 6 days, 9 days, 12 days, The number of ganglion cells was measured by immunohistochemical staining. As a result, it was confirmed that the number of living retinal ganglion cells after 6 days hardly changed in the control group (FIG. 6). On the other hand, in the experimental group treated with apotransferrin every day after induction of retinal ischemia, the number of living retinal ganglion cells was increased about 20% after 6 days compared with the control group (Fig. 7).

Having described specific portions of the present invention in detail, those skilled in the art will appreciate that these specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereto. The actual scope of the invention is thus defined by the appended claims and their equivalents.

                         SEQUENCE LISTING <110> Korea Advanced Institute of Science and Technology   <120> Composition for preventing and treating ischemic retinopathy        comprising transferrin <130> P16-B008 <160> 1 <170> PatentIn version 3.5 <210> 1 <211> 698 <212> PRT <213> Transferrin <400> 1 Met Arg Leu Ala Val Gly Ala Leu Leu Val Cys Ala Val Leu Gly Leu 1 5 10 15 Cys Leu Ala Val Pro Asp Lys Thr Val Arg Trp Cys Ala Val Ser Glu             20 25 30 His Glu Ala Thr Lys Cys Gln Ser Phe Arg Asp His Met Lys Ser Val         35 40 45 Ile Pro Ser Asp Gly Pro Ser Val Ala Cys Val Lys Lys Ala Ser Tyr     50 55 60 Leu Asp Cys Ile Arg Ala Ile Ala Ala Asn Glu Ala Asp Ala Val Thr 65 70 75 80 Leu Asp Ala Gly Leu Val Tyr Asp Ala Tyr Leu Ala Pro Asn Asn Leu                 85 90 95 Lys Pro Val Val Ala Glu Phe Tyr Gly Ser Lys Glu Asp Pro Gln Thr             100 105 110 Phe Tyr Tyr Ala Val Ala Val Val Lys Lys Asp Ser Gly Phe Gln Met         115 120 125 Asn Gln Leu Arg Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser     130 135 140 Ala Gly Trp Asn Ile Pro Ile Gly Leu Leu Tyr Cys Asp Leu Pro Glu 145 150 155 160 Pro Arg Lys Pro Leu Glu Lys Ala Val Ala Asn Phe Phe Ser Gly Ser                 165 170 175 Cys Ala Pro Cys Ala Asp Gly Thr Asp Phe Pro Gln Leu Cys Gln Leu             180 185 190 Cys Pro Gly Cys Gly Cys Ser Thr Leu Asn Gln Tyr Phe Gly Tyr Ser         195 200 205 Gly Ala Phe Lys Cys Leu Lys Asp Gly Ala Gly Asp Val Ala Phe Val     210 215 220 Lys His Ser Thr Ile Phe Glu Asn Leu Ala Asn Lys Ala Asp Arg Asp 225 230 235 240 Gln Tyr Glu Leu Leu Cys Leu Asp Asn Thr Arg Lys Pro Val Asp Glu                 245 250 255 Tyr Lys Asp Cys His Leu Ala Gln Val Ser Ser His Thr Val Val Ala             260 265 270 Arg Ser Met Gly Gly Lys Glu Asp Leu Ile Trp Glu Leu Leu Asn Gln         275 280 285 Ala Gln Glu His Phe Gly Lys Asp Lys Ser Lys Glu Phe Gln Leu Phe     290 295 300 Ser Ser Pro His Gly Lys Asp Leu Leu Phe Lys Asp Ser Ala His Gly 305 310 315 320 Phe Leu Lys Val Pro Pro Arg Met Asp Ala Lys Met Tyr Leu Gly Tyr                 325 330 335 Glu Tyr Val Thr Ala Ile Arg Asn Leu Arg Glu Gly Thr Cys Pro Glu             340 345 350 Ala Pro Thr Asp Glu Cys Lys Pro Val Lys Trp Cys Ala Leu Ser His         355 360 365 His Glu Arg Leu Lys Cys Asp Glu Trp Ser Val Asn Ser Val Gly Lys     370 375 380 Ile Glu Cys Val Ser Ala Glu Thr Thr Glu Asp Cys Ile Ala Lys Ile 385 390 395 400 Met Asn Gly Glu Ala Asp Ala Met Ser Leu Asp Gly Gly Phe Val Tyr                 405 410 415 Ile Ala Gly Lys Cys Gly Leu Val Pro Leu Ala Glu Asn Tyr Asn             420 425 430 Lys Ser Asp Asn Cys Glu Asp Thr Pro Glu Ala Gly Tyr Phe Ala Ile         435 440 445 Ala Val Val Lys Lys Ser Ala Ser Asp Leu Thr Trp Asp Asn Leu Lys     450 455 460 Gly Lys Lys Ser Cys His Thr Ala Val Gly Arg Thr Ala Gly Trp Asn 465 470 475 480 Ile Pro Met Gly Leu Leu Tyr Asn Lys Ile Asn His Cys Arg Phe Asp                 485 490 495 Glu Phe Phe Ser Glu Gly Cys Ala Pro Gly Ser Lys Lys Asp Ser Ser             500 505 510 Leu Cys Lys Leu Cys Met Gly Ser Gly Leu Asn Leu Cys Glu Pro Asn         515 520 525 Asn Lys Glu Gly Tyr Tyr Gly Tyr Thr Gly Ala Phe Arg Cys Leu Val     530 535 540 Glu Lys Gly Asp Val Ala Phe Val Lys His Gln Thr Val Pro Gln Asn 545 550 555 560 Thr Gly Gly Lys Asn Pro Asp Pro Trp Ala Lys Asn Leu Asn Glu Lys                 565 570 575 Asp Tyr Glu Leu Leu Cys Leu Asp Gly Thr Arg Lys Pro Val Glu Glu             580 585 590 Tyr Ala Asn Cys His Leu Ala Arg Ala Pro Asn His Ala Val Val Thr         595 600 605 Arg Lys Asp Lys Glu Ala Cys Val His Lys Ile Leu Arg Gln Gln Gln     610 615 620 His Leu Phe Gly Ser Asn Val Thr Asp Cys Ser Gly Asn Phe Cys Leu 625 630 635 640 Phe Arg Ser Glu Thr Lys Asp Leu Leu Phe Arg Asp Asp Thr Val Cys                 645 650 655 Leu Ala Lys Leu His Asp Arg Asn Thr Tyr Glu Lys Tyr Leu Gly Glu             660 665 670 Glu Tyr Val Lys Ala Val Gly Asn Leu Arg Lys Cys Ser Thr Ser Ser         675 680 685 Leu Leu Glu Ala Cys Thr Phe Arg Arg Pro     690 695

Claims (7)

A composition for preventing and treating ischemic retinopathy comprising transferrin as an active ingredient.
The composition of claim 1, wherein the transferrin is apotransferrin.
The composition for preventing and treating ischemic retinopathy according to claim 2, wherein the apotransferrin is represented by the amino acid sequence of SEQ ID NO: 1.
[Claim 2] The composition for preventing and treating ischemic retinopathy according to claim 1, wherein the transferrin is used for preventing and treating ischemic retinopathy by preventing apoptosis of retinal ganglion cells.
The method according to claim 1, wherein the ischemic retinopathy is selected from the group consisting of giant cell arteritis, crystalline polyarteritis, Chug-Strauss syndrome, multiple vasculitis granulomatosis, rheumatoid arthritis, sleep apnea, diabetic retinopathy, retinal vascular occlusion, (glaucoma). &lt; RTI ID = 0.0 &gt; 11. &lt; / RTI &gt;
The composition for preventing and treating ischemic retinopathy according to claim 5, wherein the glaucoma is an open-angle glaucoma.
The composition for preventing and treating ischemic retinopathy according to claim 1, wherein the composition further comprises an excipient or an additive roll.

Images